Enanta Pharmaceuticals, Inc.
NASDAQ:ENTABiotechnology
-$0.09 today
- Market cap
- $239.70M
- Beta
- 0.99
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$2.90
Volume 0.81M
Average 0.17M
ENTA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Enanta Pharmaceuticals, Inc.NASDAQ: ENTA
Depreciation & Amortization · Q2 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $1.21M rose 0.5% year over year, behind the +55.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at +19.6% a year.
Context
- Depreciation & amortization amounted to 7.8% of revenue in FY2025, up 4.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.5% toward the trailing-twelve-month pace of +55.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 5.09M USD
- Year-over-year change
- +117.9%
- 4-year CAGR
- +11.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 5.09M | +117.9% |
| FY2024 | 2024-09-30 | 2.34M | -1.5% |
| FY2023 | 2023-09-30 | 2.37M | -20.2% |
| FY2022 | 2022-09-30 | 2.97M | -10.8% |
| FY2021 | 2021-09-30 | 3.33M | — |
Depreciation & Amortization vs competitors
How ENTA compares with its peers on the latest reported figures
- ENTA's LTM Mar 2026 depreciation & amortization of $4.93M is the 3rd highest of the 11 companies compared; the peer median is $2.96M.
- Its year-over-year change of +55.9% is the 3rd highest of 11, against a peer median of -8.3%.
- Depreciation & amortization amounts to 7.1% of revenue for ENTA, versus a peer median of 10.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.54M | -16.0% | -1.1% | 3350.2% | |
| LTM Mar 2026 | $6.32M | -43.5% | +23.7% | — | |
| LTM Mar 2026 | $4.93M | +55.9% | +19.6% | 7.1% | |
| LTM Mar 2026 | $4.42M | +82.7% | +85.3% | 31.9% | |
| LTM Mar 2026 | $3.98M | -12.6% | -13.1% | 10.9% | |
| LTM Mar 2026 | $3.13M | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $2.79M | -10.3% | +0.1% | 9.9% | |
| LTM Mar 2026 | $1.67M | -6.4% | +8.9% | 10.0% | |
| LTM Mar 2026 | $786.79K | +70.5% | +36.1% | — | |
| LTM Mar 2026 | $416K | +0.0% | +17.0% | — | |
| LTM Mar 2026 | $122K | -6.2% | -36.3% | 0.2% | |
| Peer median (excluding ENTA) | $2.96M | -8.3% | +4.5% | 10.9% | |
Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 97.07M | 86.16M | 79.2M | 67.64M | 65.32M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.59M |
| Gross Profit | 97.07M | 86.16M | 79.2M | 67.64M | 60.74M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 93.0% |
| Research & Development | 174.11M | 164.52M | 163.52M | 131.48M | 106.74M |
| Selling, General & Admin | 32.54M | 45.48M | 52.89M | 57.85M | 43.93M |
| Operating Expenses | 206.65M | 210M | 216.41M | 189.33M | 146.09M |
| Depreciation & Amortization | 3.33M | 2.97M | 2.37M | 2.34M | 5.09M |
| EBITDA | (104.25M) | (119.22M) | (123.48M) | (104.51M) | (70.78M) |
| EBITDA Margin | -107.4% | -138.4% | -155.9% | -154.5% | -108.4% |
| Operating Income | (109.57M) | (123.84M) | (137.21M) | (121.69M) | (85.35M) |
| Operating Margin | -112.9% | -143.7% | -173.2% | -179.9% | -130.7% |
| Interest Income | 2.02M | 1.57M | 11.36M | 14.77M | 9.48M |
| Interest Expense | 0 | 0 | 5.15M | 10.94M | 7.68M |
| Other Income / Expenses | 1.99M | 1.66M | 6.21M | 3.9M | 1.8M |
| Income Before Tax | (107.58M) | (122.19M) | (131M) | (117.79M) | (83.55M) |
| Pre-Tax Margin | -110.8% | -141.8% | -165.4% | -174.2% | -127.9% |
| Income Tax Expense | (28.58M) | (433K) | 2.82M | (1.74M) | (1.66M) |
| Net Income | (79M) | (121.76M) | (133.82M) | (116.05M) | (81.89M) |
| Net Margin | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% |
| EPS (Basic) | (3.92) | (5.91) | (6.38) | (5.48) | (3.84) |
| EPS (Diluted) | (3.92) | (5.91) | (6.38) | (5.48) | (3.84) |
| Weighted Avg Shares | 20.17M | 20.6M | 20.97M | 21.16M | 21.34M |
| Weighted Avg Shares (Diluted) | 20.17M | 20.6M | 20.97M | 21.16M | 21.34M |
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
Intrinsic Alpha fair value
Locked
Current Price
$8.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.